| References |
1. Moon SH, Yang BY, Kim YJ, Hong MK, Lee YS, Lee DS, Chung JK, Jeong JM. Development of a complementary PET/MR dual-modal imaging probe for targeting prostate-specific membrane antigen (PSMA). Nanomedicine. 2016 May;12(4):871-879. doi: 10.1016/j.nano.2015.12.368. Epub 2015 Dec 29. PubMed PMID: 26739097. 2. Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, Armor T, Stubbs JB, Maresca KP, Stabin MG, Joyal JL, Eckelman WC, Babich JW. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013 Mar;54(3):380-7. doi: 10.2967/jnumed.112.111203. Epub 2013 Jan 9. PubMed PMID: 23303962. 3. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013 Feb;31(2):144-54. doi: 10.1016/j.urolonc.2012.04.016. Epub 2012 May 31. Review. PubMed PMID: 22658884; PubMed Central PMCID: PMC3461099. 4. Hillier SM, Kern AM, Maresca KP, Marquis JC, Eckelman WC, Joyal JL, Babich JW. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011 Jul;52(7):1087-93. doi: 10.2967/jnumed.110.086751. Epub 2011 Jun 16. PubMed PMID: 21680691. |
